ArticleJournal of the American Medical Directors Association2025
Longitudinal Pain Medication Use Among US Older Adults After a Hip Fracture.
Article in Journal of the American Medical Directors Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo describe longitudinal pain medication use, including gabapentinoid-opioid co-prescribing, among older adults discharged to a skilled nursing facility (SNF) following a hip fracture.
designRetrospective cohort study using Medicare claims linked to medication dispensing records from a large commercial SNF pharmacy. SETTING AND
participantsOlder Medicare fee-for-service beneficiaries hospitalized for a hip fracture between 2012 and 2018 who were discharged to an SNF.
methodsWe followed beneficiaries from the first day in an SNF up to 100 days to describe opioid, nonopioid analgesic, and gabapentinoid medication regimens dispensed overall and stratified by time since SNF admission, race/ethnicity, and sex.
resultsWe identified 88,433 eligible and matched individuals [average age at SNF entry = 84.8 (SD = 8.05) years, 76.7% female]. Of these, 83.7% received any pain medication in the 100 days after SNF admission. The most prevalent pain medication regimen was hydrocodone plus acetaminophen (16.7% prevalence overall), followed by oxycodone plus acetaminophen (11.2%). Dispensing of most medication regimens, particularly opioid-based regimens, declined by more than 50% by day 30 after SNF admission, with oxycodone-based regimens declining more so than hydrocodone-based ones. However, by days 60 to 100, an increase in use of several opioid-based regimens was observed. Among the 6671 individuals prescribed a gabapentinoid in the first 15 days after hospitalization, 91% were co-prescribed an opioid regardless of prior gabapentinoid use before the hip fracture. Prevalence of any pain medication dispensing was similar between sexes and race/ethnicity subgroups, but medication regimens differed by race/ethnicity. CONCLUSIONS AND IMPLICATIONS: Most older adults received pain medication after hip fracture, and multimodal opioid-containing regimens were most common. Most individuals who received a gabapentinoid immediately after SNF admission were co-prescribed an opioid. These findings suggest a need for closer medication management in SNFs to ensure adequate pain control after hip fracture while minimizing potentially harmful analgesic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.